CytRx recently announced favorable results regarding a Phase 1b/2 clinical trial with aldoxorubicin (formerly INNO-206) in patients with advanced soft tissue sarcoma. This information will be shared at the Connective Tissue Oncology Society (CTOS) 17th Annual Meeting on November 15 in Prague, Czech Republic. CytRx will be prominently featured on a poster and in discussion during the conference. The presenter will be the clinical trial’s principal investigator Dr. Sant Chawla, M.D., F.R.A.C.P. Dr. Chawla, a world renowned expert in the treatment of soft tissue sarcomas, is Director of the Sarcoma Oncology Center in Santa Monica, Calif.
“We are excited to share the powerful data from our aldoxorubicin clinical trial with experts from the international oncology community at this preeminent sarcoma conference, as well as at the upcoming ESMO 2012 Congress in Vienna, Austria,” said Steven A. Kriegsman, CytRx President and CEO. “The results from this clinical trial are impressive, especially given that these patients had failed prior chemotherapy regimens. Further, there were no observed cardiac toxicities with aldoxorubicin in this clinical trial, with cardiac toxicity considered a major dose-limiting factor for standard doxorubicin. Again, we thank Dr. Chawla for his valuable time to present at these international conferences.”
The Phase 1b/2 clinical trial results, first announced in early June 2012 at the American Society of Clinical Oncology (ASCO) conference, showed clinical benefit with aldoxorubicin at the maximum tolerated dose in 10 of 13 evaluable patients with advanced, metastatic soft tissue sarcomas who had either not responded or relapsed after receiving one to three prior chemotherapies. Eight of the thirteen patients had been treated previously with doxorubicin. CytRx holds exclusive worldwide rights to the tumor-targeting doxorubicin conjugate aldoxorubicin and to the protein-binding platform technology that serves as the linker with doxorubicin.
The Connective Tissue Oncology Society was formed in 1995. It is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues. The goal of the society is to advance the care of patients with connective tissue tumors and to increase knowledge of all aspects of the biology of these tumors, including basic and clinical research.
More information on the society is available at www.ctos.org
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
